On the basis of the data described above as well as recently reported results showing that SFN inhibits pro-survival Akt-mTOR-S6K pathway in phenotypically different breast cancer cells [45], we hypothesize that application of ITC may enhance anti-proliferative activity of 4-hydroxytamoxifen. The gene discussed is MTOR; the disease is breast carcinoma.